1246960-27-9

Evogliptin, also known as DA-1229, is a potent and selective DPP4 inhibitor (dipeptidyl peptidase 4 inhibitor). Evogliptin improves insulin resistance and delays the onset of diabetes. Evogliptin improves the insulin sensitivity in HF mice and delays the onset of diabetes in young db/db mice. DA-1229 monotherapy (5 mg for 12 weeks) improved HbA1c, fasting plasma glucose level, OGTT results and β-cell function. This drug was well tolerated in Korean subjects with type 2 diabetes mellitus.

依格列汀 是一种口服有效的 DPP4 抑制剂，在小鼠模型中具有显著而持久的降糖效果。Evogliptin hydrochloride 还可通过诱导自噬来抑制肝细胞的炎症和纤维化信号的产生。Evogliptin hydrochloride 可用于 2 型糖尿病、骨质疏松症，肾功能损害以及慢性肝脏炎症的研究。